• KOL
    • Malignant Glioma
    • Allan H Friedman
    • Allan H Friedman: Influence Statistics

      Allan H Friedman

      Allan H Friedman

      Show email address

      2Division of Neurosurgery, Duke University Medical Center, Durham, North Carolina. | Duke University Medical Center: Duke University Hospital | Division of Neurosurgery, Duke ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Allan H Friedman:Expert Impact

      Concepts for whichAllan H Friedmanhas direct influence:Malignant glioma,Radiation therapy,Recurrent glioblastoma,Malignant gliomas,Daily temozolomide,Sciatic nerve,Glioblastoma multiforme.

      Allan H Friedman:KOL impact

      Concepts related to the work of other authors for whichfor which Allan H Friedman has influence:Brain tumors,Malignant gliomas,Isocitrate dehydrogenase,Glioblastoma multiforme,Subarachnoid hemorrhage,Central nervous,Tumor cells.

      KOL Resume for Allan H Friedman

      Year
      2021

      2Division of Neurosurgery, Duke University Medical Center, Durham, North Carolina.

      Duke University Medical Center: Duke University Hospital

      2020

      Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina, USA.

      Duke University Medical Center, Durham, NC, USA

      2019

      The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina

      2018

      Department of Neurosurgery, Duke University, Durham, North Carolina.

      The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.

      2017

      4, Department of Neurosurgery, Duke University Medical Center, Durham, NC, United States

      Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.

      2016

      Division of Neurosurgery, Duke University Medical Center, 1000 Trent Drive 4520 Hosp South, Box 3807, 27710, Durham, NC, USA

      2015

      Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC

      Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina

      2014

      Duke Cancer Institute, Duke University Medical Center Department of Surgery Durham North Carolina

      1Division of Neurosurgery, Department of Surgery,

      2013

      Department of Pathology, Duke University Medical Center, The Preston Robert Tisch Brain Tumor Center at Duke, and Pediatric Brain Tumor Foundation Institute at Duke, Durham, NC

      Division of Neurosurgery

      2012

      Division of Neurosurgery, Duke University Medical Center, Durham, North Carolina, United States

      Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, 200 Trent Drive, Durham, NC 27710, USA

      2011

      Authors' Affiliations: Departments of 1Surgery, 2Neurology, 3Pediatrics, 4Medicine, 5Radiation Oncology, and 6Cancer Center Biostatistics, Duke University Medical Center, Durham, North Carolina

      Division of Neurosurgery, Department of Surgery, Duke University Medical Center, P.O. Box 3807, Durham, NC 27710, USA

      1Preston Robert Tisch Brain Tumor Center;

      All authors: Duke University Medical Center, Durham, NC.

      2010

      Departments of Neurosurgery and Interventional Radiology, Froedtert Hospital, Milwaukee, Wisconsin

      Division of Neurosurgery, Duke University Medical Center, 27710, Durham, NC, USA

      From the Duke University Medical Center, Durham, NC

      and the University of Texas M. D. Anderson Cancer Center, Houston, TX.

      4Preston Robert Tisch Brain Tumor Center, Duke University, Durham, North Carolina;

      2009

      Department of Surgery, Duke University Medical Center, Box 3624, 27710, Durham, NC, USA

      3Division of Neurosurgery, Duke University Medical Center, Durham, North Carolina

      Duke University Medical Center, Durham, NC; Duke University Medical Center, Durham, NC

      2008

      From the *Department of Biomedical Engineering, Duke University, Durham, North Carolina; †Division of Neurosurgery, The Ottawa Hospital, Ottawa, Canada; and Divisions of ‡Neurosurgery, and §Orthopedic Surgery, Duke University Medical Center, Durham, North Carolina.

      Division of Neurosurgery, Department of Surgery, Box 3807 Med Ctr, Preston Robert Tisch Brain Tumor Center at Duke University, Durham, NC 27710, USA.

      The Preston Robert Tisch Brain Tumor Center at Duke, DUMC Box 3624, Durham, NC 27710, USA

      2007

      Department of Surgery, The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, 27710, Durham, NC, USA

      From the Preston Robert Tisch Brain Tumor Center

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Allan H Friedman is among the top experts in the world.
      Concept World rank
      molecular approaches treatment #1
      technical advances ability #1
      failed radiation treatment #1
      drez lesions treatment #1
      nmd fluorodeoxyglucose f18 #1
      removal hemosiderinstained brain #1
      simvastatintreated placebo #1
      efficacy drez lesions #1
      intraventricular schwannomas #1
      tumor regrowth symptoms #1
      cerebellar gbm #1
      046 analysis #1
      abnormal thoracic nerves #1
      gliomas cerebellum #1
      tentorial detachment technique #1
      therapy substantia gelatinosa #1
      sah statins #1
      bilateral atrophy patients #1
      precise microsurgical techniques #1
      acoustic neuroma variation #1
      gray matter nmd #1
      gbm immunohistochemistry #1
      glioblastoma resistant #1
      svsp intervention #1
      tumor histology #1
      pseudoneoplasms skull base #1
      malignant glioma purpose #1
      vasospasm simvastatintreated #1
      relationship arcuate eminence #1
      presence independent focus #1
      intracranial opening #1
      injury neurotization #1
      intractable pain trauma #1
      correlation ahv #1
      gbm karnofsky performance #1
      1 mesial #1
      time symptomatic vasospasm #1
      clivus relationship #1
      ssc middle ear #1
      surgical microanatomy #1
      39 patients trauma #1
      hyponatremia bnp #1
      atl seizure onset #1
      standard treatment paradigm #1
      symptomatic vasospasm svsp #1
      glossopharyngeal nerve tumor #1
      method dural opening #1
      independent focus #1
      v3 tmj #1
      occipital condyles clivus #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Allan H Friedman

      KOL-Index: 15338

      PURPOSE: The prognosis for patients with recurrent glioblastoma multiforme is poor, with a median survival of 3 to 6 months. We performed a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irinotecan.

      PATIENTS AND METHODS: This phase II trial included two cohorts of patients. The initial cohort, comprising 23 patients, received bevacizumab at 10 mg/kg plus irinotecan every 2 weeks. The dose of irinotecan was based on the ...

      Known for Irinotecan Patients | Monoclonal Antibodies | Phase Trial | Glioblastoma Multiforme | 6 Weeks
      KOL-Index: 14327

      OBJECTIVE: Endothelial damage and intimal proliferation occur in vasospastic cerebral arteries after subarachnoid hemorrhage (SAH). In the peripheral vasculature, endothelial damage increases intimal matrix metalloproteinase-9 (MMP-9) and vascular endothelial growth factor (VEGF) levels, causing neointimal proliferation. We hypothesized that serum von Willebrand factor (vWF) (a marker of endothelial cell death), MMP-9, and VEGF levels could serve as prognostic markers in predicting the ...

      Known for Cerebral Vasospasm | Growth Factor | Sah Mmp9 | Subarachnoid Hemorrhage | Matrix Metalloproteinase
      KOL-Index: 14191

      PURPOSE: To determine if the addition of bevacizumab to radiation therapy and temozolomide, followed by bevacizumab, temozolomide, and irinotecan, for newly diagnosed glioblastoma patients is safe and effective.

      EXPERIMENTAL DESIGN: A total of 75 patients with newly diagnosed glioblastoma were enrolled in the phase II trial that investigated the addition of bevacizumab to standard radiation therapy and daily temozolomide followed by the addition of bevacizumab and irinotecan to adjuvant ...

      Known for Radiation Therapy | Bevacizumab Temozolomide | Monoclonal Antibodies | Newly Diagnosed Glioblastoma | Phase Trial
      KOL-Index: 14119

      OBJECTIVE: Serum brain natriuretic peptide (BNP) is elevated after subarachnoid hemorrhage (SAH), causes diuresis and natriuresis (cerebral salt wasting), and may exacerbate delayed ischemic neurological deficits. We examined the temporal relationship between serum BNP elevation, hyponatremia, and the onset of delayed ischemic neurological deficits and determined whether serum BNP levels correlated with the 2-week outcome after SAH.

      METHODS: Serum BNP and sodium were measured ...

      Known for Subarachnoid Hemorrhage | Sah Patients | Natriuretic Peptide | Neurological Deficits | Bnp Levels
      KOL-Index: 13646

      Human cytomegalovirus (HCMV) has been described to be associated with several human malignancies, though the frequency of detection remains controversial. It is unclear whether HCMV plays an active role in malignant tumor progression or becomes reactivated under pathologic conditions that result in chronic inflammation or immunosuppression. In this study, we report on the investigation of detecting HCMV in the tumors and peripheral blood of patients with newly diagnosed glioblastoma ...

      Known for Peripheral Blood | Patients Gbm | Human Cytomegalovirus | Viral Dna | Sensitive Detection
      KOL-Index: 13510

      PURPOSE: Recurrent grade III-IV gliomas have a dismal prognosis with minimal improvements in survival seen following currently available salvage therapy. This study was conducted to determine if the combination of a novel antiangiogenic therapy, bevacizumab, and a cytotoxic agent, irinotecan, is safe and effective for patients with recurrent grade III-IV glioma.

      EXPERIMENTAL DESIGN: We conducted a phase II trial of bevacizumab and irinotecan in adults with recurrent grade III-IV glioma. ...

      Known for Recurrent Malignant Glioma | Bevacizumab Irinotecan | Monoclonal Antibodies | Phase Trial | Grade Iii
      KOL-Index: 13209

      PURPOSE: We performed a phase II study to evaluate the combination of imatinib mesylate, an adenosine triphosphate mimetic, tyrosine kinase inhibitor, plus hydroxyurea, a ribonucleotide reductase inhibitor, in patients with recurrent glioblastoma multiforme (GBM).

      PATIENTS AND METHODS: Patients with GBM at any recurrence received imatinib mesylate plus hydroxyurea (500 mg twice a day) orally on a continuous, daily schedule. The imatinib mesylate dose was 500 mg twice a day for patients ...

      Known for Imatinib Mesylate | Hydroxyurea Patients | Glioblastoma Multiforme | 500 Day | Median Pfs
      KOL-Index: 12985

      BACKGROUND: The efficacy of carboplatin, irinotecan, and bevacizumab among recurrent glioblastoma (GBM) patients after prior progression on bevacizumab therapy in a phase 2, open-label, single-arm trial was evaluated.

      METHODS: Eligible patients received carboplatin (area under the plasma curve [AUC] 4 mg/ml-min) on day 1, whereas bevacizumab (10 mg/kg) and irinotecan (340 mg/m(2) for patients on CYP3A enzyme-inducing anti-epileptics [EIAEDs] and 125 mg/m(2) for patients not on EIAEDs) ...

      Known for Bevacizumab Therapy | Carboplatin Irinotecan | Patients Progression | Humanized Antineoplastic | Phase 2
      KOL-Index: 12927

      Frequent mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) and the promoter of telomerase reverse transcriptase (TERT) represent two significant discoveries in glioma genomics. Understanding the degree to which these two mutations co-occur or occur exclusively of one another in glioma subtypes presents a unique opportunity to guide glioma classification and prognosis. We analyzed the relationship between overall survival (OS) and the presence of IDH1/2 and TERT promoter ...

      Known for Tert Promoter | Adult Malignant Gliomas | Idh1 2 Mutations | Isocitrate Dehydrogenase | Reverse Transcriptase
      KOL-Index: 12744

      BACKGROUND: Surgical site infections increase the incidence of morbidity and mortality as well as health-care expenses. The cost of care increases threefold to fourfold as a consequence of surgical site infection after spinal surgery. The aim of the present study was to determine the role of subcutaneous fat thickness in the development of surgical site infection following cervical spine fusion surgery.

      METHODS: We performed a retrospective review of a consecutive cohort of 213 adult ...

      Known for Subcutaneous Fat | Surgical Site Infection | Cervical Spine | Fusion Surgery | 95 Confidence Interval
      KOL-Index: 12474

      Brain metastases are a common and devastating complication in patients with malignant melanoma. Therapeutic options for these patients are limited, and the prognosis is usually poor.

      OBJECT: A retrospective review of 6953 patients with melanoma treated at a single institution was undertaken to identify demographic factors associated with the development of clinically significant brain metastases in 702 of these patients and to determine the factors influencing the prognosis of this ...

      Known for Brain Metastases | Malignant Melanoma | Factors Development | Neoplasms Survival | Single Institution
      KOL-Index: 12367

      PURPOSE: We conducted a two-phase clinical trial in patients with progressive malignant glioma (MG). The first phase of this trial was designed to determine the dose of O6-BG effective in producing complete depletion of tumor AGT activity for 48 hours. The second phase of the trial was designed to define the maximum tolerated dose (MTD) of a single dose of temozolomide when combined with O6-BG. In addition, plasma concentrations of O6-BG and O6-benzyl-8-oxoguanine were evaluated after ...

      Known for Continuous Infusion | O6 Bg | Trial Temozolomide | Malignant Glioma | Agt Activity
      KOL-Index: 11685

      BACKGROUND: In the current study, the authors report a Phase II trial of irinotecan (CPT-11), a topoisomerase I inhibitor active against malignant glioma (MG), with celecoxib, a selective COX-2 inhibitor, among MG patients with recurrent disease.

      METHODS: Patients with MG at any type of recurrence received CPT-11, administered as a 90-minute intravenous infusion on Weeks 1, 2, 4, and 5 of each 6-week cycle plus celecoxib, which was administered continuously at a dose of 400 mg twice a ...

      Known for Cpt11 Dose | Patients Eiaeds | Phase Trial | Irinotecan Celecoxib | Recurrent Malignant

      Key People For Malignant Glioma

      Top KOLs in the world
      #1
      John Gregory Cairncross
      malignant glioma elderly patients oligodendroglial tumors
      #2
      Michael Weller
      glioma cells newly diagnosed glioblastoma multiple sclerosis
      #3
      Darell D D Bigner
      monoclonal antibodies brain tumors cell lines
      #4
      Roger Stupp
      newly diagnosed glioblastoma radiation therapy adjuvant temozolomide
      #5
      Martin J van den Bent
      recurrent glioblastoma response assessment brain metastases
      #6
      Alba Ariela Brandes
      recurrent glioblastoma elderly patients breast cancer

      2Division of Neurosurgery, Duke University Medical Center, Durham, North Carolina. | Duke University Medical Center: Duke University Hospital | Division of Neurosurgery, Duke University Medical Center, Durham, NC, USA | Duke University Health System,

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.